Drug safety in, biogenerics out of House panel’s PDUFA reauthorization
Executive Summary
New FDA drug safety authority is on the agenda as the House Energy and Commerce Committee writes PDUFA reauthorization legislation, but contentious issues, such as a regulatory pathway for approving generic biologics, are likely to be left for another day, given the shortage of time for debate. Stakeholders' hopes that the panel would keep drug safety out of the user fee reauthorization legislation were dashed, in part, by the May 21 release of findings that GSK's Avandia poses a cardiac risk for diabetics. In response to the Avandia news, Chairman John Dingell, D-Mich., vowed to address the "dangerous shortcomings" in drug safety at the agency. User fees must be renewed by July 31 if FDA is to avoid taking steps to begin staff reductions (1"The Pink Sheet" May 21, 2007, p. 17). The committee plans to have an FDA bill ready for floor action when the House returns from its July 4 recess. The Senate passed its version of the bill on May 9...
You may also be interested in...
User Fee Reauthorization Needed By August To Avoid Staff Layoffs
FDA will initiate staff layoffs if Congress does not reauthorize prescription drug user fees by August, HHS Deputy Assistant Secretary for Budget and Health Science Legislation Craig Burton warned May 17
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.